Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
News|Articles|September 2, 2005
- Pharmaceutical Technology-09-02-2005
- Volume 29
- Issue 9
In the Spotlight-September 2005
Pharmaceutical science and technology innovation
Articles in this issue
about 21 years ago
Securing the Supply Chain With RFIDabout 21 years ago
Applications of Poly(ethylene in Drug Delivery Systems: Part IIabout 21 years ago
Analytical Method Equivalency: An Acceptable Analytical Practiceabout 21 years ago
September 2005about 21 years ago
Pilots and Partnerships Move RFID Forwardabout 21 years ago
Reshaping CMC Development Servicesabout 21 years ago
Wash. Rinse. Repeatabout 21 years ago
Outsourcing Atrophy: A Cautionary TaleRelated to this article
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
3
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
4
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
5